Cell-autonomous and cell-nonautonomous mechanisms of neurodegeneration appear to occur in the proteinopathies, including Alzheimer's and Parkinson's diseases. However, how neuronal toxicity is generated from misfolding-prone proteins secreted by nonneuronal tissues and whether modulating protein aggregate levels at distal locales affects the degeneration of postmitotic neurons remains unknown. We generated and characterized animal models of the transthyretin (TTR) amyloidoses that faithfully recapitulate cell-nonautonomous neuronal proteotoxicity by expressing human TTR in the muscle. We identified sensory neurons with affected morphological and behavioral nociception-sensing impairments. Nonnative TTR oligomer load and neurotoxicity increased following inhibition of TTR degradation in distal macrophage-like nonaffected cells. Moreover, reducing TTR levels by RNAi or by kinetically stabilizing natively folded TTR pharmacologically decreased TTR aggregate load and attenuated neuronal dysfunction. These findings reveal a critical role for modulation of aggregation-prone degradation that directly affects postmitotic tissue degeneration observed in the proteinopathies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099907PMC
http://dx.doi.org/10.1073/pnas.1801117115DOI Listing

Publication Analysis

Top Keywords

ttr
7
cellular clearance
4
clearance circulating
4
circulating transthyretin
4
transthyretin decreases
4
decreases cell-nonautonomous
4
cell-nonautonomous proteotoxicity
4
proteotoxicity cell-autonomous
4
cell-autonomous cell-nonautonomous
4
cell-nonautonomous mechanisms
4

Similar Publications

A Case of Transthyretin Cardiac Amyloidosis Coexisting With Rheumatoid Arthritis.

Cureus

December 2024

Graduate Medical Education (GME) Internal Medicine, Mary Washington Healthcare, Fredericksburg, USA.

Cardiac amyloidosis is a rare but increasingly recognized cause of heart failure, often underdiagnosed until later stages of the disease. This report describes a case of transthyretin amyloidosis (ATTR) in a 68-year-old male patient with a significant medical history of rheumatoid arthritis (RA), a combination seldom documented in the literature. The patient presented with progressive symptoms of heart failure, and diagnostic testing confirmed ATTR cardiac amyloidosis through pyrophosphate (PYP) scanning.

View Article and Find Full Text PDF

Transthyretin-Related Familial Amyloidosis Polyneuropathy with Spinal Cord Damage: A Case Report.

Int Med Case Rep J

January 2025

Department of Neurology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang Cerebrovascular Disease (Stroke) Clinical Medical Research Center, Regional Medical Center for Neurological Diseases of Henan Province, Luoyang, People's Republic of China.

Introduction: Transthyretin protein-related familial amyloidosis polyneuropathy (TTR-FAP) is an autosomal dominant genetic disease caused by mutations in the TTR gene. The disease is characterized primarily by peripheral and autonomic nerve damage. Disease progression is associated with frequent involvement of the heart, lungs, kidneys, eyes, and other organs.

View Article and Find Full Text PDF

Background: Currently there is no way to determine if archived cerebrospinal fluid (CSF) specimens have been properly handled and can be considered suitable for research purposes. Transthyretin (TTR) is abundant in CSF and undergoes a redox reaction that shifts its native proteoform into an S‐cysteinylated form. This reaction proceeds spontaneously ex vivo when CSF is thawed, but ceases at storage temperatures of ‐80°C.

View Article and Find Full Text PDF

Background: The differential diagnosis of Alzheimer’s disease (AD) and normal pressure hydrocephalus (NPH) is complicated by overlapping clinical manifestations. This challenges accurate clinical diagnosis and highlights the need for molecular level investigations to understand underlying pathologies. There have been few proteomic investigations into NPH, which were limited by low sample sizes and limited analytical depth.

View Article and Find Full Text PDF

Background: Neurofilament light protein (NfL) is a promising biomarker of neuronal injury and neurodegeneration. NfL levels in cerebrospinal fluid (CSF) and blood provide information about disease progression and are increasingly relied on as outcome measure in clinical trials. Understanding NfL kinetics is critical for interpreting NfL in response to new events where a steady state cannot be assumed, such as acute injury, disease onset or progression, or response to disease‐modifying therapies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!